Loncastuximab Tesirine Demonstrated Substantial Single-Agent Efficacy and Manageable Safety Profile in Heavily Pretreated Chinese Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

被引：2

作者：

Lin, Ningjing ^{[1
]}

Sun, Xiuhua ^{[2
]}

Zhou, Hui ^{[3
]}

Zou, Liqun ^{[4
]}

Zhou, Keshu ^{[5
]}

Liu, Lihong ^{[6
]}

Yang, Haiyan ^{[7
]}

Hu, Kai ^{[8
]}

Cai, Qingqing ^{[9
]}

Liu, Yao ^{[10
]}

Jin, Jie ^{[11
]}

Zhang, Liling ^{[12
]}

Li, Wenyu ^{[13
]}

Guo, Ye ^{[14
]}

Yang, Wei ^{[15
]}

Luo, Feng ^{[16
]}

Li, Yanyan ^{[16
]}

Zhang, Mengqi ^{[16
]}

Lu, Feinan ^{[16
]}

Song, Yuqin ^{[17
]}

Zhu, Jun ^{[18
]}

机构：

[1] Beijing Canc Hosp, Dept Lymphat Oncol, Beijing, Peoples R China

[2] Dalian Med Univ, Hosp 2, Dalian, Peoples R China

[3] Cent South Univ, Hunan Canc Hosp, Affiliated Canc Hosp, Xiangya Sch Med, Changsha, Peoples R China

[4] Sichuan Univ, West China Hosp, Chengdu, Peoples R China

[5] Zhengzhou Univ, Henan Canc Hosp, Dept Hematol, Canc Hosp, Zhengzhou, Peoples R China

[6] Hebei Med Univ, Hosp 4, Shijiazhuang, Hebei, Peoples R China

[7] Zhejiang Canc Hosp, Dept Lymphat Oncol, Hangzhou, Peoples R China

[8] Beijing Boren Hosp, Dept Adult Lymphoma, Beijing, Peoples R China

[9] Sun Yat Sen Univ, Canc Cente, Guangzhou, Peoples R China

[10] Chongqing Univ, Canc Hosp, Chongqing, Peoples R China

[11] Zhejiang Univ, Dept Hematol, Affiliated Hosp 1, Sch Med, Hangzhou, Peoples R China

[12] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Ctr Canc, Wuhan, Peoples R China

[13] Guangdong Prov Peoples Hosp, Guangzhou, Peoples R China

[14] Shanghai East Hosp, Shanghai, Peoples R China

[15] China Med Univ, Dept Hematol, Shengjing Hosp, Shenyang, Peoples R China

[16] Overland Pharmaceut, Shanghai, Peoples R China

[17] Peking Univ, Key Lab Carcinogenesis & Translat Res, Dept Lymphoma, Minist Educ Beijing,Canc Hosp & Inst, Beijing, Peoples R China

[18] Peking Univ, Canc Hosp, Beijing, Peoples R China

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-173645

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 50 条

[1] Long-term survival projections of loncastuximab tesirine-treated patients in relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
Hamadani, Mehdi
Graham, Christopher N.
Liao, Laura
Zhang, Katherine H.
Strat, Hannah
Ungar, David
Ai, Weiyun Z.
Chen, Lei
Carlo-Stella, Carmelo
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[2] Loncastuximab Tesirine in the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Juarez-Salcedo, Luis Miguel
Nimkar, Santosh
Corazon, Ana Maria
Dalia, Samir
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (14)
[3] Efficacy and Safety of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Caimi, Paolo F.
Ai, Weiyun Z.
Alderuccio, Juan Pablo
Ardeshna, Kirit M.
Hamadani, Mehdi
Hess, Brian T.
Kahl, Brad S.
Radford, John A.
Solh, Melhem
Stathis, Anastasios
Zinzani, Pier Luigi
Feingold, Jay
Ungar, David
Qin, Yajuan
He, Shui
Carlo-Stella, Carmelo
BLOOD, 2020, 136
[4] Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma: a profile of its use in the USA
Anthony Markham
Zaina T. Al-Salama
Drugs & Therapy Perspectives, 2022, 38 : 261 - 267
[5] Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma: a profile of its use in the USA
Markham, Anthony
Al-Salama, Zaina T.
DRUGS & THERAPY PERSPECTIVES, 2022, 38 (06) : 261 - 267
[6] Glofitamab plus Polatuzumab Vedotin demonstrates durable responses and a manageable safety profile in patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
Dietrich, S.
Hutchings, M.
Avigdor, A.
Sureda, A.
Terol, M. J.
Bosch, F.
Corradini, P.
Larsen, Stauffer T.
Dominguez, Rueda A.
Skarbnik, A.
Jorgensen, J.
Goldschmidt, N.
Gurion, R.
Zinzani, P. L.
Pinto, A.
Cordoba, R.
Bottos, A.
Huang, Z.
Simko, S.
Relf, J.
de L'Etang, Filezac A.
Sellam, G.
Gritti, G.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 209 - 209
[7] Loncastuximab tesirine: an effective therapy for relapsed or refractory diffuse large B-cell lymphoma
Xu, Bo
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 78 (05) : 707 - 719
[8] Loncastuximab tesirine: an effective therapy for relapsed or refractory diffuse large B-cell lymphoma
Bo Xu
European Journal of Clinical Pharmacology, 2022, 78 : 707 - 719
[9] Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma: a review of clinical data
Furqan, Fateeha
Hamadani, Mehdi
THERAPEUTIC ADVANCES IN HEMATOLOGY, 2022, 13
[10] Evaluating efficacy and safety of loncastuximab tesirine injection for the treatment of adult patients with relapsed or refractory large B-cell lymphoma
Ahmed, Nausheen
Hamadani, Mehdi
EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (12) : 1313 - 1320

← 1 2 3 4 5 →